Veradermics, Inc — Form 8-K
Filed October 19, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Veradermics announced positive topline results from Study 304, a Phase 3 trial of VDPHL01 (extended-release oral minoxidil) in 536 male patients with mild-to-moderate pattern hair loss. VDPHL01 8.5mg once-daily achieved 28.6 hairs/cm² increase vs. 6.6 for placebo (p<0.0001); twice-daily achieved 36.4 hairs/cm² (p<0.0001). Patient-reported outcomes: 55.7% (once-daily) and 68.7% (twice-daily) reported 'improved' or 'much improved' vs. 15.0% placebo (p<0.0001). Safety: no treatment-related serious adverse events, no cardiac adverse events of special interest; adverse event rates low (peripheral edema 2.8–4.5%, hypertrichosis 2.2–9.0%). This follows positive April 2026 Study 302 results; combined data covers 1,000+ male patients. Female trial (Study 306) enrollment complete; data expected H1 2027.
Why this rating
Lead asset cleared major Phase 3 hurdle with robust efficacy/safety. First potential oral non-hormonal PHL treatment in 30 years; $825.7M company; $30B market opportunity. Clear regulatory pathway forward; still requires FDA approval, female data, and commercialization execution.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $117.01 ▲ 1.77% | at our read · unknown $114.97 | +10 min · unknown $118.83 ▲ 3.35% | +30 min · unknown $114.72 ▼ 0.22% | +1 hr pending | +4 hrs pending |
The stock had already moved -1.74% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 19, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.